There has been a recent abundance of articles (old info though) that have been published from tons of different sources as of late. All referring to the 3D liver surviving 40 days. It seems more and more are finally taking notice and perhaps even getting excited about it. Here is a snipit from engineeringDOTcom's article (written yesterday).
"Over the course of the printed organ’s 40 day life, Organovo researchers exposed the tissue to acetaminophen, both a pain killer and a liver toxin. To the researchers delight, their experiments proved that the printed livers could filter toxins all on their own.
With that milestone achieved, Orgonovo has plans to launch a 3D printed human liver product sometime in 2014. While Organovo is quick to point out that fully mature 3D printed livers are still a long way off, this new development could prove useful for companies engineering drugs too. According to Kevin Murphy, Organovo’s CEO, “[T]he fact that these tissues demonstrate similar activity to native liver when presented with a known challenge drug is an encouraging indication of utility in drug development.""
It was originally slated for late, but since they received good results earlier than expected it may be moved up. Nobody really knows for sure.
The application numbers are actually:
These are what you need to enter on the uspto.gov website
But these were all just provisional applications, and all have expired. I have not been able to find any non-provisoinal applications by ONVO.
If anyone is interested in the 3D stocks, this one kind of ties in with pharma. This company is in the 3d bio-printing area and announced success in printing live human liver tissue a while back. They have serveral partnerships with big pharma, colleges & even make-up companies (L'Oreal). I have been in it since sub 5 and plan on holding for a long while. I wouldn't recommend buying in today (it has risen almost 20% the past 2 days), but it should pull back some soon. Do your own DD though. I just thought I'd bring this up if anyone was interested in checking it out.
It is NEVER a bad thing to take a profit. In all reality, there may be a bit of pullback after a quick jump 12%. I'd feel comfortable taking some profit and looking to jump back in later on. GL
They have 1 more settlement on their website, but it is for promoting medical devices. That fine was only 130k I believe.
Doesn't look too bad. I just cannot figure out the SEC part of it all.
I went back and re-read some of the old articles (Mikey's included) and thought I'd post this just in case some of you have not seen it and/or never looked for it. I got this from the USAO Eastern PA's website:
Novartis - 2010
Case: 1) Promoting Trileptal off label 2)Provided remuneration to induce promotion and/or prescribing of Diovan, Zelnorm, Sandostatin, Exforge & Tekturna 3) As a result, they caused false or fraudulent claims to be submitted to Medicare, etc.
Settlement: $237.5 Mil
Eli Lilly - 2008
Case: 1) Promoted the sale and use of Zyprexa to Dr.'s for "unapproved uses". 2) They implemented a marketing strategy to promote Zyprexa to Dr.'s for unapproved uses. 3) They encouraged Dr's to prescribe higher amounts than the recommended dose. 4) As a result, they caused false or fraudulent claims to be submitted to Medicare, etc.
Settlement: $438.2 Mil
Cephalon - 2008
Case: 1) Knowingly and willfully promoted the sale and use of Actiq, Gabitril & Provigil for "unapproved uses". 3) As a result, they caused false or fraudulent claims to be submitted to Medicare, etc.
Settlement: $375 Mil
Astra Zeneca - 2010
Case: 1) Promoted the sale and use of Seroquel to Dr.'s for certain uses that were not approved by the FDA. 2) promoted the unapproved uses by engaging in: improperly influencing the content of speakers in company-sponsored programs; engaged dr.s to give promotional programs it controlled on unapproved uses; engaged dr.s to conduct studies on unapproved uses; recruited dr.s to serve as authors of articles largely prepared by medical literatrure companies about studies they did not conduct on unapproved uses; used those studies and articles as the basis for promotional messages about unapproved uses. 3) Offered and paid illegal remuneration to dr.s
Settlement: $520 Mil
Are these one in the same? I have only seen Questcor's purchase of Acthar from Aventis (now part of Sanofi I believe). Sorry if this is a dumb question, I'm just getting lost with the vast amount of messages going on here...
Are we talking about 2 different things here? Did Armour turn into Aventis or were they all merged into another company? This is talking about Acthar Gel Synthetic (seractide acetate) Injection, which is not the same as (repository corticotropin) Injection right?
This stock has been a day trader's play ground though. Short when it is 8% up, then buy when it is 4% down. Making money both ways.
I'm pretty sure the SA article has nothing to do with the price action. It raises no new information. Just a rehash.
SA Pumper? Far from it.
You are correct in the acquistion, I used the wrong word (bought). But as for your headline '...sell over 400k' That is still incorrect. He has only sold 100k.